Skip to Main Content

WASHINGTON — As lawmakers took aim at high insulin costs, two major insulin manufacturers increased their lobbying spending last year, according to new federal disclosures.

Insulin has become the poster child for dysfunction in the drug pricing debate, and lawmakers are considering enacting insulin-specific policies including allowing Medicare to negotiate prices for all insulin products and capping out-of-pocket monthly costs for patients in Medicare and the private insurance market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment